Amendments to the Claims:

Claims 1-27 (Cancelled)

Claim 28 (Currently Amended): An antibody immunologically specific for an isolated human PD2 protein consisting having the sequence of SEQ ID NO: 2, wherein said human PD2 protein is about 531 amino acid in length and comprises an amino terminal helix-loop-helix domain and a centrally localized nuclear transport signal and nucleotide binding site.

Claim 29 (Previously Presented): The antibody of claim 28, which is a monoclonal antibody.

Claim 30 (Previously Presented): The antibody of claim 28, which is a polyclonal antibody.

Claim 31 (Currently Amended): A method for detecting human PD2 protein having the sequence consisting of SEQ ID NO: 2, or a fragment thereof in a sample, comprising:

- a) obtaining a sample suspected of containing the human PD2 protein or the fragment thereof;
- b) contacting said sample with the antibody as claimed in claim 28, under conditions effective to allow the formation of immune complexes; and
 - c) detecting the immune complexes so formed.

Claim 32 (Previously Presented): The method of claim 31, wherein said antibody is linked to a detectable label.

Claim 33 (Previously Presented): The method of claim 32, wherein said detectable label is selected from the group consisting of a radioactive, a fluorescent, a biological, and an enzymatic label.

Claim 34 (Currently Amended): A kit for detecting human PD2 protein having the sequence consisting of SEQ ID NO: 2 or a

fragment thereof in a sample, comprising the antibody as claimed in claim 28 and optionally <u>said PD2</u> protein for use <u>as</u> a positive control and instructional material.

Claim 35 (Currently Amended): The kit of claim 34 33, wherein said antibody is linked to a detectable label.

Claim 36 (Previously Presented): The kit of claim 35, wherein said detectable label is selected from the group consisting of a radioactive, a fluorescent, a biological, and an enzymatic label.